|
MRI News Service:
'Clinical Trial' p4 |
|
|
|
 |
 | | | '''Results from a large, worldwide, clinical trial show evidence that a first-of-its-kind pacemaker system is safe and effective to use during magnetic resonance imaging (MRI). During the trial, no MRI-related complications were reported in patients with ...' | | Thursday, 6 January 2011 by www.healthcanal.com |
|
|
|
| | | '''Magnetic resonance imaging (MRI) analyses from two Phase 3 clinical trials showed that once every four week subcutaneous injections of SIMPONI® (golimumab) 50 mg plus methotrexate resulted in statistically significant improvements in markers of ...' | | | Monday, 8 November 2010 by www.prnewswire.com | |
|
|
|
| | | '''InSightec Ltd., the global leader in MR guided focused ultrasound technology and the only company to receive FDA approval for its ExAblate(R) system for treating uterine fibroids, announced today that its ExAblate(R) system has been used for the first ...' | | | Tuesday, 31 August 2010 by www.newswire.ca | |
|
|
|
| | | '''New recommendations to protect participant safety in clinical trials of certain Alzheimer's disease drugs have been accepted by the U.S. Food and Drug Administration (FDA) and are already being incorporated into research studies. These safety ...' | | | Monday, 12 July 2010 by www.prnewswire.com | |
|
|
|
| | | '''Do we need a revision of current recommendations for breast cancer screening- According to a recent prospective multicenter cohort study published in the 'Journal of Clinical Oncology', this appears advisable at least for young women carrying an ...' | | | Friday, 26 February 2010 by www.news-medical.net | |
|
|
|
| | | '''Repligen Corporation (Nasdaq: RGEN) reported today that it has completed patient treatment in its Phase 3 clinical trial of RG1068, synthetic human secretin, in magnetic resonance imaging (MRI) of the pancreas. The study is designed to assess the ...' | | | Monday, 19 October 2009 by au.sys-con.com | |
|
|
|
| | | '''Monrovia, CA, January 02, 2009 --(PR.com)-- Dr. Charles Peterfy, Chief Scientific Officer at Synarc will give the featured address entitled 'Successful Multi-Site MRI in Rheumatoid Arthritis Clinical Trials: Overcoming Single-Site Mindedness.' at ...' | | | Friday, 2 January 2009 by www.pr.com | |
|
|
|
| | | '''WALTHAM, Mass., March 26 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company has initiated a Phase 3 clinical trial to evaluate the use of RG1068, synthetic human secretin, to improve the assessment of ...' | | | Wednesday, 26 March 2008 by www.prnewswire.com | |
|
|
|
| | | '''ScienceDaily (Oct. 28, 2007) — Several recent studies demonstrate the flexibility of targeted therapy techniques, where new drugs can be developed and tested in human trials more quickly and safely than ever before. Among the studies presented include a ...' | | | Sunday, 28 October 2007 by www.sciencedaily.com | |
|
|
|
| | | '''A technique that significantly boosts the sensitivity of magnetic resonance imaging (MRI) is on the verge of clinical trials which, if successful, could allow doctors to assess the effects of cancer drugs on a tumour within hours. Kevin Brindle of ...' | | | Monday, 8 October 2007 by www.rsc.org:80 | |
|
|
|
|
|
|
|
|
| Result Pages |
|
|
|
|
|
A common mistake that people make when trying to design something completely
foolproof is to underestimate the ingenuity of complete fools.
- Douglas Adams |
|
|
News
top
